| Psoriasis vulgaris
Hadlima vs Ultravate
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Hadlima vs Ultravate with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUltravate has a higher rate of injection site reactions vs Hadlima based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ultravate but not Hadlima, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Hadlima
Ultravate
At A Glance
SC injection
Every other week
TNF-alpha blocker
Topical
Twice daily
Topical corticosteroid
Indications
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Hidradenitis Suppurativa
- Uveitis
- Psoriasis vulgaris
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.
Juvenile polyarthritis SC every other week based on weight for patients 2 years and older: 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), or 40 mg (>=30 kg).
Crohn Disease Adults: 160 mg Day 1, 80 mg Day 15, then 40 mg every other week starting Day 29; pediatric patients >=6 years: weight-based induction (80 or 160 mg Day 1, 40 or 80 mg Day 15), then 20 or 40 mg every other week starting Day 29.
Ulcerative Colitis 160 mg Day 1, 80 mg Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by Day 57.
Psoriasis vulgaris, Uveitis 80 mg initial dose, then 40 mg every other week starting 1 week after the initial dose.
Hidradenitis Suppurativa 160 mg Day 1, 80 mg Day 15, then 40 mg every week or 80 mg every other week starting Day 29.
Psoriasis vulgaris Apply a thin layer to affected skin twice daily for up to two weeks; total dosage should not exceed 50 grams (50 ml) per week.
Contraindications
—
—
Adverse Reactions
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, nausea, accidental injury, urinary tract infection, hyperlipidemia, flu syndrome, abdominal pain, laboratory test abnormalities.
Serious Serious infections (pneumonia, septic arthritis, erysipelas, cellulitis, diverticulitis, pyelonephritis), malignancies, hypersensitivity reactions, hepatitis B reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity.
Postmarketing Liver failure, hepatitis, autoimmune hepatitis, sarcoidosis, Merkel cell carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, systemic vasculitis, deep vein thrombosis.
Most common (>=1%) Telangiectasia, application site atrophy, headache
Less common (<1%, >0.1%) Application site discoloration, herpes zoster, influenza, nasopharyngitis, otitis media acute, throat infection, wound, increased blood pressure
Pharmacology
TNF-alpha blocker; adalimumab-bwwd is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, also lysing surface TNF-expressing cells in vitro in the presence of complement.
Halobetasol propionate is a super-high potency topical corticosteroid that plays a role in cellular signaling, immune function, inflammation, and protein regulation; the precise mechanism of action in plaque psoriasis is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Hadlima
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Ultravate
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Hadlima
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (2/8) · Qty limit (2/8)
Ultravate
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Hadlima
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Ultravate
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Hadlima.
No savings programs available for Ultravate.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HadlimaView full Hadlima profile
UltravateView full Ultravate profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.